首頁 › 慢性淋巴性白血病 › 俄亥俄州 › Columbus
Columbus, OH 的 慢性淋巴性白血病 臨床試驗
28 項針對 慢性淋巴性白血病 的研究正在 Columbus（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
招募中3 期
- Ohio State University Comprehensive Cancer Center, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- 還有 8 項
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- 還有 8 項
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
招募中3 期
- Study Site 104, Columbus
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
招募中3 期
- Ohio State University Comprehensive Cancer Center, Columbus
Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
招募中2 期
- The Ohio State University, Columbus
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
招募中1/2 期
- Research Site, Columbus
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
招募中1 期
- The James Cancer Hospital and Solove Research Institute, Columbus
Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
招募中3 期
- OSU Comprehensive Cancer Center, Columbus
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
招募中1/2 期
- The Ohio State University Wexner Medical Center, Columbus
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
招募中1 期
- The Ohio State University, Columbus
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
招募中1 期
- Nationwide Children's Hospital, Columbus
- Ohio State University Comprehensive Cancer Center, Columbus
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
招募中1 期
- The Ohio State University, Columbus
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
招募中4 期
- Ohio State University Comprehensive Cancer Center, Columbus
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
招募中4 期
- Ohio State University Comprehensive Cancer Center, Columbus
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
Study of SGR-1505 in Mature B-Cell Neoplasms
招募中1 期
- The Ohio State University - The James Cancer Hospital, Columbus
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
招募中2 期
- The Ohio State University /ID# 230439, Columbus
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
招募中2 期
- The Ohio State University Comprehensive Cancer Center, Columbus
Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
招募中1 期
- The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
HPC Offered for PRESERVE Expansion
招募中觀察性研究
- The Ohio State University Medical Center, Columbus
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
招募中1/2 期
- The Ohio State University Comprehensive Cancer Center, Columbus
其他城市的 慢性淋巴性白血病 試驗
- Boston, MA31 項研究
- Durham, NC27 項研究
- Washington, DC22 項研究
- Seattle, WA20 項研究
- Rochester, MN19 項研究
- New York City, NY18 項研究
- Houston, TX17 項研究
- Baldwin Park, CA16 項研究
- Milwaukee, WI15 項研究
- Chicago, IL14 項研究
- Cincinnati, OH14 項研究
- Nashville, TN13 項研究
Columbus 的其他研究
- 非小細胞肺癌56 項研究
- 乳癌39 項研究
- 卵巢癌39 項研究
- 癌症（所有類型）38 項研究
- 肺癌37 項研究
- 急性髓系白血病35 項研究
- 轉移性癌症27 項研究
- 子宮內膜癌25 項研究
- 大腸直腸癌24 項研究
- 前列腺癌24 項研究
- 多發性骨髓瘤24 項研究
- 黑色素瘤21 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。